ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy
ZUG, Switzerlan... Biopharmaceuticals, Oncology, RegulatoryShire plc, ONIVYDE, irinotecan, nal-IRI, metastatic pancreatic cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Pharmaceuticals | Study